Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study.

Autor:	Anthony MS; RTI Health Solutions, Research Triangle Park, NC., Aroda VR; Brigham and Women's Hospital, Boston, MA., Parlett LE; Carelon Research, Wilmington, DE., Djebarri L; Sanofi, Chilly-Mazarin, France., Berreghis S; Sanofi, Chilly-Mazarin, France., Calingaert B; RTI Health Solutions, Research Triangle Park, NC., Beachler DC; Carelon Research, Wilmington, DE., Crowe CL; Carelon Research, Wilmington, DE., Johannes CB; RTI Health Solutions, Waltham, MA., Juhaeri J; Sanofi, Inc., Bridgewater, NJ., Lanes S; Carelon Research, Wilmington, DE., Pan C; Sanofi, Inc., Bridgewater, NJ., Rothman KJ; RTI Health Solutions, Waltham, MA., Saltus CW; RTI Health Solutions, Waltham, MA., Walsh KE; Boston Children's Hospital, Boston, MA.
Jazyk:	angličtina
Zdroj:	Diabetes care [Diabetes Care] 2024 Apr 01; Vol. 47 (4), pp. 712-719.
DOI:	10.2337/dc23-1911
Abstrakt:	Objective: To assess risk of anaphylaxis among patients with type 2 diabetes mellitus who are initiating therapy with a glucagon-like peptide 1 receptor agonist (GLP-1 RA), with a focus on those starting lixisenatide therapy. Research Design and Methods: A cohort study was conducted in three large, U.S. claims databases (2017-2021). Adult (aged ≥18 years) new users of a GLP-1 RA who had type 2 diabetes mellitus and ≥6 months enrollment in the database before GLP-1 RA initiation (start of follow-up) were included. GLP-1 RAs evaluated were lixisenatide, an insulin glargine/lixisenatide fixed-ratio combination (FRC), exenatide, liraglutide or insulin degludec/liraglutide FRC, dulaglutide, and semaglutide (injectable and oral). The first anaphylaxis event during follow-up was identified using a validated algorithm. Incidence rates (IRs) and 95% CIs were calculated within each medication cohort. The unadjusted IR ratio (IRR) comparing anaphylaxis rates in the lixisenatide cohort with all other GLP-1 RAs combined was analyzed post hoc. Results: There were 696,089 new users with 456,612 person-years of exposure to GLP-1 RAs. Baseline demographics, comorbidities, and use of other prescription medications in the 6 months before the index date were similar across medication cohorts. IRs (95% CIs) per 10,000 person-years were 1.0 (0.0-5.6) for lixisenatide, 6.0 (3.6-9.4) for exenatide, 5.1 (3.7-7.0) for liraglutide, 3.9 (3.1-4.8) for dulaglutide, and 3.6 (2.6-4.9) for semaglutide. The IRR (95% CI) for the anaphylaxis rate for the lixisenatide cohort compared with the pooled other GLP-1 RA cohort was 0.24 (0.01-1.35). Conclusions: Anaphylaxis is rare with GLP-1 RAs. Lixisenatide is unlikely to confer higher risk of anaphylaxis than other GLP-1 RAs. (© 2024 by the American Diabetes Association.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu